Sanofi Consumer Healthcare India Surges Ahead: 28% Revenue Growth in Q2

Sanofi Consumer Healthcare India Limited (BSE: 544250 | NSE: SANOFICONR) has reported a robust 28% year-on-year revenue growth for the second quarter of 2025, reaching ₹2,209 million. The company’s Profit After Tax (PAT) stood at ₹607 million, marking a 21% jump over the previous quarter. The performance was driven by multiple growth levers, including the commencement of export operations, a focused product portfolio, and successful product launches. Sales rose by 27.5% over Q1 2025 and 27.6% over Q2 2024, reflecting strong operational momentum.

Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said: “Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy—driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that focused approach, with successful relaunch of two previously recalled products and introduction of a new product. We also commenced export operations allowing us to extend our efforts towards international markets. As we look ahead, we remain steadfast in our purpose to make self-care simpler, more accessible and effective for consumers.”

During the first half of 2025, Sanofi introduced Allegra D in the allergy segment and successfully relaunched Depura 60k and Combiflam Suspension, which were voluntarily recalled last year. Legacy brands like Avil and Depura continue to uphold consumer trust and drive relevance in their respective categories. In Kolkata, Sanofi Consumer Healthcare’s Q2 performance has echoed positively, with distributors noting a surge in demand across pharmacies and modern trade outlets. The relaunch of Depura 60k and Combiflam Suspension has been well-received, quickly regaining traction among healthcare providers and consumers alike. The introduction of Allegra D has added a fresh boost, especially in urban clusters where allergy-related products see high seasonal uptake. With Kolkata’s consumer base increasingly leaning toward trusted, science-backed healthcare solutions, Sanofi’s strong brand recall and renewed product momentum are positioning it for sustained market growth in the region.